Avilar: Targeted degradation for extracellular proteins

Avilar is designing extracellular protein degraders by harnessing a natural process through which proteins are internalized and degraded in the liver. Though the company isn’t revealing its lead targets or indications, the approach should be applicable to an array of extracellular proteins in the liver and those that circulate through it.

The company concept originated at RA Capital Management, which has invested in several intracellular protein degradation companies. In 2019, RA posed the question to its team: can degradation be applied to extracellular proteins?...